After a mixed quarter: Teva strengthens its innovative activity, raises forecasts and tries to reduce its dependence on generic drugs • The company exceeded revenue forecasts with $4.14 billion in the second quarter, but the profit line showed weakness, mainly due to one-time expenses related to the acquisition of Emalex